Loading...
Docoh

Blueprint Medicines (BPMC)

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

Company profile

Ticker
BPMC
Exchange
CEO
Jeffrey Albers
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Blueprint Medicines Security Corporation • Blueprint Medicines (Switzerland) GmbH • Blueprint Medicines (Netherlands) B.V. • Blueprint Medicines (UK) Ltd. • Blueprint Medicines (Germany) GmbH • Blueprint Medicines Spain, S.L. • Blueprint Medicines (France) SAS • Blueprint Medicines (Italy) S.r.L. • Lengo Therapeutics, Inc. ...

BPMC stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

2 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 178.57M 178.57M 178.57M 178.57M 178.57M 178.57M
Cash burn (monthly) (no burn) 30.08M 52.19M 57.96M 39.42M 30.06M
Cash used (since last report) n/a 88.77M 154.05M 171.07M 116.35M 88.72M
Cash remaining n/a 89.8M 24.52M 7.5M 62.22M 89.85M
Runway (months of cash) n/a 3.0 0.5 0.1 1.6 3.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 Aug 22 Debra Durso-Bumpus Common Stock Sell Dispose S No Yes 75.11 5,000 375.55K 40,836
24 Aug 22 Debra Durso-Bumpus Common Stock Option exercise Acquire M No Yes 15.01 5,000 75.05K 45,836
24 Aug 22 Debra Durso-Bumpus Stock Option Common Stock Option exercise Dispose M No Yes 15.01 5,000 75.05K 40,836
22 Aug 22 Jeffrey W. Albers Common Stock Sell Dispose S No Yes 71.3 662 47.2K 183,243
22 Aug 22 Jeffrey W. Albers Common Stock Sell Dispose S No Yes 70.47 7,748 546K 183,905
22 Aug 22 Jeffrey W. Albers Common Stock Option exercise Acquire M No Yes 15.01 8,410 126.23K 191,653
22 Aug 22 Jeffrey W. Albers Stock Option Common Stock Option exercise Dispose M No Yes 15.01 8,410 126.23K 30,000
19 Aug 22 Jeffrey W. Albers Common Stock Sell Dispose S No Yes 70.02 1,590 111.33K 183,243
19 Aug 22 Jeffrey W. Albers Common Stock Option exercise Acquire M No Yes 15.01 1,590 23.87K 184,833
19 Aug 22 Jeffrey W. Albers Stock Option Common Stock Option exercise Dispose M No Yes 15.01 1,590 23.87K 38,410
13F holders Current Prev Q Change
Total holders 233 247 -5.7%
Opened positions 33 37 -10.8%
Closed positions 47 70 -32.9%
Increased positions 79 83 -4.8%
Reduced positions 85 89 -4.5%
13F shares Current Prev Q Change
Total value 3.22B 3.85B -16.2%
Total shares 63.35M 59.81M +5.9%
Total puts 186.8K 106.8K +74.9%
Total calls 431.5K 180.8K +138.7%
Total put/call ratio 0.4 0.6 -26.7%
Largest owners Shares Value Change
FMR 8.58M $433.18M +60.8%
TROW T. Rowe Price 5.63M $284.46M +14.2%
Vanguard 5.62M $283.71M +1.7%
BLK Blackrock 5.28M $266.68M -1.9%
STT State Street 2.72M $137.21M +19.8%
Wellington Management 2.5M $126.26M -36.1%
Cadian Capital Management 2.02M $102.06M +5.2%
JPM JPMorgan Chase & Co. 1.72M $87.11M +2.9%
MS Morgan Stanley 1.66M $83.89M +639.9%
Alliancebernstein 1.5M $75.63M -0.9%
Largest transactions Shares Bought/sold Change
FMR 8.58M +3.24M +60.8%
MS Morgan Stanley 1.66M +1.44M +639.9%
Wellington Management 2.5M -1.41M -36.1%
TROW T. Rowe Price 5.63M +698.56K +14.2%
Healthcare Of Ontario Pension Plan Trust Fund 685K +685K NEW
STT State Street 2.72M +449.65K +19.8%
BEN Franklin Resources 0 -413.67K EXIT
Casdin Capital 1.15M -400K -25.8%
Citadel Advisors 69.26K -365.48K -84.1%
Avidity Partners Management 0 -291.18K EXIT

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: absolute, Adjacent, ATM, bear, Borisy, borrow, Borrower, chairman, choice, collateral, Connecticut, correspondingly, coupled, CTDPA, Dable, death, default, Demetri, deruxtecan, detrimental, disadvantage, dissolved, drew, EHA, endometrial, environment, EpimAb, exact, fill, flexibility, floor, fluid, forecasted, fundamental, Garnich, Garnish, George, Habib, ICAV, IDRx, inflationary, Jefferey, Lamont, loan, lock, Lydon, monetization, nonclinical, organizational, OS, Overnight, proportion, proportionately, reaction, redeem, refinance, Relay, repaid, repayment, resignation, retire, Rowland, score, secondary, shutdown, SOFR, stream, Street, successor, symptom, Synthetic, SystImmune, Tao, tool, tranche, trastuzumab, TSS, unanimously, unpaid, vacancy, variable
Removed: home, imaging, margin, reclassified